What is Sopharma AD-Sofia Earnings Yield (Joel Greenblatt) %?
Sopharma AD-Sofia's Enterprise Value for the quarter that ended in Dec. 2023 was лв1,144 Mil.
Sopharma AD-Sofia's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was лв122 Mil. Sopharma AD-Sofia's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was 10.66%.
The historical rank and industry rank for Sopharma AD-Sofia's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
XBUL:SFA'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.03 Med: 7.64 Max: 15.12
Current: 10.5
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Sopharma AD-Sofia was 15.12%. The lowest was 4.03%. And the median was 7.64%.
XBUL:SFA's Earnings Yield (Joel Greenblatt) % is ranked better than 68.32% of 101
companies
in the Medical Distribution industry
Industry Median: 5.85
vs XBUL:SFA: 10.50
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Sopharma AD-Sofia's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 10.69%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Sopharma AD-Sofia Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Sopharma AD-Sofia's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sopharma AD-Sofia's Earnings Yield (Joel Greenblatt) %
For the Medical Distribution subindustry, Sopharma AD-Sofia's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia's Earnings Yield (Joel Greenblatt) % Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Sopharma AD-Sofias Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as
Sopharma AD-Sofia's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was лв122 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Sopharma AD-Sofia Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Sopharma AD-Sofia's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are organized based on the production of finished products which include Tablet dosage forms, Ampoule dosage forms, Medical products, Other forms, and Other revenue. Geographically company operates in Bulgaria and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XBUL:SFA has been successfully added to your 